ABIVAX Société Anonyme (EPA:ABVX)

Market Cap	8.19B
Revenue (ttm)	6.02M
Net Income (ttm)	-195.39M
Shares Out	75.57M
EPS (ttm)	-3.09
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	15,870
Average Volume	139,753
Open	110.60
Previous Close	108.40
Day's Range	110.60 - 112.80
52-Week Range	4.51 - 112.80
Beta	-0.11
RSI	70.43
Earnings Date	Dec 15, 2025

About ABIVAX Société Anonyme

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod that is in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis, as well as in Phase 2b clinical trial to treat patients with Crohn’s disease. The company was incorporated in 2013 and is headquartered in Paris, France.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2013
• Employees: 69
• Stock Exchange: Euronext Paris
• Ticker Symbol: ABVX

Financial Performance

In 2024, ABIVAX Société Anonyme's revenue was 10.79 million, an increase of 135.94% compared to the previous year's 4.57 million. Losses were -176.24 million, 19.3% more than in 2023.